Sign In
Buy ADPT
$22.57
-1.61 (-6.66%)
At Close: Jul 31, 2026
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
04:05pm, Tuesday, 15'th Jul 2025
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
10:40am, Friday, 04'th Jul 2025
Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
07:30am, Tuesday, 01'st Jul 2025
clonoSEQ® is now integrated into Flatiron Health's OncoEMR®, simplifying MRD testing access for over 4,500 clinicians across the Flatiron network.
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
10:51am, Thursday, 26'th Jun 2025
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t
What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock
01:01pm, Friday, 13'th Jun 2025
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
10:46am, Wednesday, 11'th Jun 2025
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syste
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
04:05pm, Wednesday, 28'th May 2025
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syste
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
10:46am, Monday, 26'th May 2025
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?
01:05pm, Friday, 09'th May 2025
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
11:02am, Thursday, 08'th May 2025
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
10:45am, Thursday, 08'th May 2025
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.
Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript
09:46pm, Thursday, 01'st May 2025
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chi
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:05pm, Thursday, 01'st May 2025
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wal
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
06:40pm, Thursday, 01'st May 2025
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.
